/WVE
WVE Stock - Wave Life Sciences Ltd.
Healthcare|BiotechnologyNASDAQ
$15.98+2.83%
+$0.44 (+2.83%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+90.4%upside
Target: $30.43
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for WVE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.82 – $16.14
TARGET (TP)$30.43
STOP LOSS$14.70
RISK/REWARD1:11.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.72
52W High$21.73
52W Low$5.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $108.30M | $113.31M | $3.65M | $40.96M | $20.08M |
| Gross Profit | $108.30M | $113.31M | $3.65M | $40.96M | $-110,867,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -552.2% |
| Operating Income | $-110,403,000 | $-67,996,000 | $-162,720,000 | $-127,016,000 | $-153,377,000 |
| Net Income | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 | $-149,910,000 |
| Net Margin | -89.6% | -50.8% | -4434.7% | -298.4% | -746.7% |
| EPS | $-0.70 | $-0.54 | $-2.05 | $-2.36 | $-3.82 |
Company Overview
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Visit WebsiteRating Distribution
Strong Buy
1
8%
Buy / Outperform
11
85%
Hold / Neutral
1
8%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
12 Bullish1 Neutral/Bearish
Price Targets
$16
Average Target
↑ 2.9% Upside
Now
$5
Low
$16
Average
$33
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Wedbush | Reiterated | Outperform | $33← $20 |
| December 9th 2025 | RBC Capital Mkts | Upgrade | Outperform | $27 |
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $18 |
| August 4th 2025 | Canaccord Genuity | Initiation | Buy | $19 |
| July 28th 2025 | Oppenheimer | Initiation | Outperform | $24 |
| July 16th 2025 | Citigroup | Initiation | Buy | $16 |
| June 11th 2025 | Raymond James | Resumed | Outperform | $14 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $10 |
| April 8th 2025 | Wedbush | Initiation | Outperform | $18 |
| February 25th 2025 | Jefferies | Initiation | Buy | $26 |
| October 16th 2024 | Raymond James | Upgrade | Strong Buy | $22 |
| September 27th 2024 | JP Morgan | Resumed | Overweight | $13← $10 |
| September 19th 2024 | B. Riley Securities | Initiation | Buy | $11 |
| September 9th 2024 | JP Morgan | Initiation | Overweight | $10 |
| May 15th 2024 | Wells Fargo | Initiation | Overweight | $11 |
Earnings History & Surprises
WVEBeat Rate
33%
Last 18 quarters
Avg Surprise
-18.2%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
+21.1%
$-0.15vs$-0.19
Q2 24
-33.3%
$-0.24vs$-0.18
Q3 24
-56.3%
$-0.25vs$-0.16
Q4 24
-67.9%
$-0.47vs$-0.28
Q1 25
+200.0%
$0.17vs$-0.17
Q2 25
-7.4%
$-0.29vs$-0.27
Q3 25
-6.9%
$-0.31vs$-0.29
Q4 25
-6.7%
$-0.32vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-0.28 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q3 2025 | Jul 30, 2025 | $-0.29 | $-0.31 | -6.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.27 | $-0.29 | -7.4% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $-0.17 | $0.17 | +200.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.28 | $-0.47 | -67.9% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.16 | $-0.25 | -56.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.18 | $-0.24 | -33.3% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.18 | $0.07 | +138.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.32 | $-0.20 | +37.5% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.06 | $-0.27 | -550.0% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-0.42 | $-0.47 | -11.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.48 | $-0.42 | +12.5% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.56 | $-0.62 | -10.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.56 | $-0.62 | -10.7% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $-0.47 | $-0.61 | -29.8% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.64 | $-0.12 | +81.3% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.61 | $-0.78 | -27.9% | ✗ MISS |
Latest News
WAVE Life Sciences shares are trading higher after HC Wainwright & Co. raised the price target from $22 to $30.
📈 PositiveBenzinga•Dec 19, 2025, 06:11 PM
HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Raises Price Target to $30
📈 PositiveBenzinga•Dec 19, 2025, 04:21 PM
Oppenheimer Maintains Outperform on WAVE Life Sciences, Raises Price Target to $32
📈 PositiveBenzinga•Dec 16, 2025, 03:03 PM
Truist Securities Maintains Buy on WAVE Life Sciences, Raises Price Target to $50
📈 PositiveBenzinga•Dec 15, 2025, 02:36 PM
B. Riley Securities Maintains Buy on WAVE Life Sciences, Raises Price Target to $37
📈 PositiveBenzinga•Dec 12, 2025, 02:59 PM
Wedbush Maintains Outperform on WAVE Life Sciences, Raises Price Target to $33
📈 PositiveBenzinga•Dec 12, 2025, 12:40 PM
Wave Life Sciences shares are trading lower after the company announced the pricing of its upsized $250 million public offering.
📉 NegativeBenzinga•Dec 10, 2025, 01:48 PM
Reported Earlier, Wave Life Sciences Prices Upsized $350M Public Offering Of 15,789,475 Ordinary Shares At $19.00 And 2.63M Pre-Funded Warrants
➖ NeutralBenzinga•Dec 10, 2025, 08:20 AM
Citigroup Maintains Buy on WAVE Life Sciences, Raises Price Target to $30
📈 PositiveBenzinga•Dec 9, 2025, 07:45 PM•Also:
Canaccord Genuity Maintains Buy on WAVE Life Sciences, Raises Price Target to $40
📈 PositiveBenzinga•Dec 9, 2025, 06:55 PM•Also:
Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $29
📈 PositiveBenzinga•Dec 9, 2025, 06:05 PM
Wave Life Sciences upgraded at RBC following data for obesity asset WVE-007
📈 PositiveSeeking Alpha•Dec 9, 2025, 04:49 PM
Wave Life Sciences shares are trading higher after the company announced a $250 million public offering. Multiple firms raised their respective price targets on the stock.
📈 PositiveBenzinga•Dec 9, 2025, 02:08 PM
Cantor Fitzgerald Maintains Overweight on WAVE Life Sciences, Raises Price Target to $34
📈 PositiveBenzinga•Dec 9, 2025, 01:50 PM
Clear Street Maintains Buy on WAVE Life Sciences, Raises Price Target to $47
📈 PositiveBenzinga•Dec 9, 2025, 12:20 PM
RBC Capital Upgrades WAVE Life Sciences to Outperform, Raises Price Target to $27
📈 PositiveBenzinga•Dec 9, 2025, 12:06 PM
Wave Life Sciences Announces Proposed $250M Public Offering Of Ordinary Shares And Pre-Funded Warrants
➖ NeutralBenzinga•Dec 8, 2025, 09:05 PM
Wave Life Sciences closes up 147% on positive early data from obesity drug trial
📈 PositiveSeeking Alpha•Dec 8, 2025, 03:12 PM
WVE shares are trading higher after the company reported positive interim Phase 1 data showing its obesity drug WVE-007 delivered GLP-1-like fat loss at three months without muscle loss and was generally safe and well tolerated.
📈 PositiveBenzinga•Dec 8, 2025, 12:40 PM
Wave Life Sciences Announces Interim Data From Lowest Therapeutic Cohort Of Ongoing First-In-Human INLIGHT Trial Evaluating WVE-007 For Obesity Treatment
➖ NeutralBenzinga•Dec 8, 2025, 12:32 PM
Frequently Asked Questions about WVE
What is WVE's current stock price?
Wave Life Sciences Ltd. (WVE) is currently trading at $15.98 per share. The stock has moved +2.83% today.
What is the analyst price target for WVE?
The average analyst price target for WVE is $30.43, based on 1 analyst.
What sector is Wave Life Sciences Ltd. in?
Wave Life Sciences Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is WVE's market cap?
Wave Life Sciences Ltd. has a market capitalization of $2.62 billion, making it a mid-cap company.
Does WVE pay dividends?
No, Wave Life Sciences Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
Explore stocks similar to WVE for comparison